震裕科技(300953.SZ):公司已建成一條行星滾柱絲桿半自動產線並投入批量生產
格隆匯3月4日丨震裕科技(300953.SZ)近日在接受現場調研時表示,公司已建成一條行星滾柱絲桿半自動產線並投入批量生產,日產能已拓展到50套,自建絲桿綜合測試實驗室已投入使用,可自主完成對絲桿導程精度、傳動效率、萬次壽命跑合等關鍵參數的檢測及驗證,爲滿足市場的需求,公司已開始建設第二條半自動產線,預計2025年Q1投入使用。基於行業客戶對絲桿組件精度一致性的高要求,公司還計劃在年內建設一條集加工、在線檢測、裝配於一體的全自動絲桿生產線,進一步提高從1-N大規模量產的一致性及穩定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.